Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACRS NASDAQ:ELVN NASDAQ:IMNM NASDAQ:KOD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$4.36-7.4%$4.33$1.34▼$5.15$657.82M0.761.20 million shs928,946 shsELVNEnliven Therapeutics$34.71-2.2%$41.44$14.78▼$48.53$2.16B0.29724,930 shs1.08 million shsIMNMImmunome$18.58-5.6%$22.01$7.96▼$27.65$2.23B2.041.18 million shs895,710 shsKODKodiak Sciences$31.05-9.1%$39.76$3.43▼$47.84$2.14B2.21638,104 shs1.45 million shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics+6.56%+3.06%-0.84%+53.92%+192.55%ELVNEnliven Therapeutics-1.50%-12.69%-14.65%+20.55%+59.22%IMNMImmunome-0.66%-12.69%-14.84%-6.46%+118.18%KODKodiak Sciences+0.86%-5.43%-19.92%+37.41%+760.45%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$4.36-7.4%$4.33$1.34▼$5.15$657.82M0.761.20 million shs928,946 shsELVNEnliven Therapeutics$34.71-2.2%$41.44$14.78▼$48.53$2.16B0.29724,930 shs1.08 million shsIMNMImmunome$18.58-5.6%$22.01$7.96▼$27.65$2.23B2.041.18 million shs895,710 shsKODKodiak Sciences$31.05-9.1%$39.76$3.43▼$47.84$2.14B2.21638,104 shs1.45 million shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics+6.56%+3.06%-0.84%+53.92%+192.55%ELVNEnliven Therapeutics-1.50%-12.69%-14.65%+20.55%+59.22%IMNMImmunome-0.66%-12.69%-14.84%-6.46%+118.18%KODKodiak Sciences+0.86%-5.43%-19.92%+37.41%+760.45%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRSAclaris Therapeutics 3.13Buy$11.50164.06% UpsideELVNEnliven Therapeutics 2.83Moderate Buy$61.8078.37% UpsideIMNMImmunome 2.85Moderate Buy$33.1778.34% UpsideKODKodiak Sciences 2.63Moderate Buy$42.1436.06% UpsideCurrent Analyst Ratings BreakdownLatest ACRS, IMNM, KOD, and ELVN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2026ELVNEnliven Therapeutics MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$45.00 ➝ $62.006/2/2026ACRSAclaris Therapeutics Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$13.006/1/2026ACRSAclaris Therapeutics Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/28/2026IMNMImmunome Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$36.00 ➝ $37.005/28/2026IMNMImmunome BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$36.005/28/2026IMNMImmunome BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$36.005/15/2026IMNMImmunome Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$37.00 ➝ $33.005/13/2026IMNMImmunome HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$40.005/12/2026ELVNEnliven Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$80.005/11/2026ELVNEnliven Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/11/2026KODKodiak Sciences Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$14.00 ➝ $61.00(Data available from 6/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRSAclaris Therapeutics$8.37M72.69N/AN/A$0.85 per share5.12ELVNEnliven TherapeuticsN/AN/AN/AN/A$7.74 per shareN/AIMNMImmunome$4.02M524.56N/AN/A$5.75 per share3.23KODKodiak SciencesN/AN/AN/AN/A$2.97 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRSAclaris Therapeutics-$64.92M-$0.56N/AN/AN/A-832.58%-55.89%-38.49%8/6/2026 (Estimated)ELVNEnliven Therapeutics-$103.69M-$1.67N/AN/AN/AN/A-21.04%-20.41%8/12/2026 (Estimated)IMNMImmunome-$212.39M-$2.38N/AN/AN/AN/A-51.15%-47.32%8/5/2026 (Estimated)KODKodiak Sciences-$229.97M-$4.17N/AN/AN/AN/A-253.85%-81.48%8/12/2026 (Estimated)Latest ACRS, IMNM, KOD, and ELVN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026IMNMImmunome-$0.60-$0.48+$0.12-$0.48$0.22 millionN/A5/7/2026Q1 2026ACRSAclaris Therapeutics-$0.16-$0.15+$0.01-$0.15$1.32 million$2.00 million5/7/2026Q1 2026ELVNEnliven Therapeutics-$0.44-$0.38+$0.06-$0.38N/AN/A5/7/2026Q4 2025KODKodiak Sciences-$0.93-$0.94-$0.01-$0.94N/AN/A3/31/2026Q4 2025KODKodiak Sciences-$1.02-$1.04-$0.02-$1.04N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACRSAclaris TherapeuticsN/AN/AN/AN/AN/AELVNEnliven TherapeuticsN/AN/AN/AN/AN/AIMNMImmunomeN/AN/AN/AN/AN/AKODKodiak SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRSAclaris TherapeuticsN/A4.034.03ELVNEnliven TherapeuticsN/A40.3240.32IMNMImmunomeN/A21.6821.68KODKodiak SciencesN/A3.543.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRSAclaris Therapeutics98.34%ELVNEnliven Therapeutics95.08%IMNMImmunome44.58%KODKodiak Sciences89.06%Insider OwnershipCompanyInsider OwnershipACRSAclaris Therapeutics4.80%ELVNEnliven Therapeutics3.00%IMNMImmunome7.21%KODKodiak Sciences45.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACRSAclaris Therapeutics100139.66 million132.96 millionOptionableELVNEnliven Therapeutics5060.91 million59.08 millionOptionableIMNMImmunome40113.25 million105.09 millionOptionableKODKodiak Sciences9062.58 million33.86 millionOptionableACRS, IMNM, KOD, and ELVN HeadlinesRecent News About These CompaniesKodiak Sciences Inc. (KOD) Presents at Jefferies Global Healthcare Conference 2026 - SlideshowJune 5 at 5:32 AM | seekingalpha.comKodiak Sciences Stockholders Back Directors and Governance ProposalsJune 4 at 7:30 PM | tipranks.comKodiak Stock Rises 35% in 3 Months: Here's What You Need to KnowJune 4 at 12:07 PM | zacks.comKodiak Sciences to Present at 2026 Jefferies Global Healthcare ConferenceMay 28, 2026 | prnewswire.comWhy One Healthcare Fund Increased Its Kodiak Sciences Stake Amid an Eye-Popping RallyMay 17, 2026 | fool.comKodiak Sciences (KOD) price target increased by 16.91% to 66.30May 14, 2026 | msn.comChardan Capital upgrades Kodiak Sciences (KOD)May 11, 2026 | msn.comA Look At Kodiak Sciences (KOD) Valuation After Positive Phase 3 GLOW2 Results For ZenkudaMay 11, 2026 | finance.yahoo.comKodiak Sciences (NASDAQ:KOD) Upgraded to Buy at Chardan CapitalMay 11, 2026 | marketbeat.comZenkuda Phase 3 Win and Expanding Pipeline Might Change The Case For Investing In Kodiak Sciences (KOD)May 10, 2026 | finance.yahoo.comKodiak Sciences Inc.: Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial ResultsMay 8, 2026 | finanznachrichten.deKodiak's Q1 Loss Wider Than Expected, Pipeline Development in FocusMay 8, 2026 | zacks.comKodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial ResultsMay 7, 2026 | prnewswire.comKodiak Sciences (KOD) Expected to Announce Earnings on WednesdayMay 6, 2026 | marketbeat.comKodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific ConferencesApril 30, 2026 | prnewswire.comKodiak Sciences (KOD) Up 2% Since Last Earnings Report: Can It Continue?April 30, 2026 | zacks.comKodiak Sciences Inc (KOD): What’s the Chance of Success for Zenkuda?April 24, 2026 | finance.yahoo.comKodiak Sciences (NASDAQ:KOD) Signals Behind Surge Points To MomentumApril 16, 2026 | kalkinemedia.comKKodiak Sciences (KOD) reports Q4 EPS of ($1.05)April 12, 2026 | msn.comKodiak Sciences (KOD) price target increased by 56.62% to 56.71April 10, 2026 | msn.comJ.P. Morgan Reaffirms Their Buy Rating on Kodiak Sciences (KOD)April 8, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACRS, IMNM, KOD, and ELVN Company DescriptionsAclaris Therapeutics NASDAQ:ACRS$4.36 -0.35 (-7.43%) Closing price 04:00 PM EasternExtended Trading$4.32 -0.04 (-0.92%) As of 06:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.Enliven Therapeutics NASDAQ:ELVN$34.71 -0.78 (-2.20%) Closing price 04:00 PM EasternExtended Trading$34.74 +0.03 (+0.10%) As of 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.Immunome NASDAQ:IMNM$18.58 -1.10 (-5.59%) Closing price 04:00 PM EasternExtended Trading$18.88 +0.30 (+1.62%) As of 05:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.Kodiak Sciences NASDAQ:KOD$31.05 -3.11 (-9.10%) Closing price 04:00 PM EasternExtended Trading$30.46 -0.60 (-1.92%) As of 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? Buy the Dip? Broadcom's AI Moat Is Wider Than Ever The Market Has Ollie’s Bargain Outlet Completely Wrong Broadcom's Whiplash: Shares Tank After Pre-Earnings Surge Navitas: NVIDIA’s AI Power Broker? Macy's Delivers Strong Q1, Raises Outlook, but Wall Street Remains Cautious NVIDIA's New Power Play: Why Fluence Is Surging Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
